Celularity, Inc. (CELU)
1.26
+0.10
(+8.62%)
USD |
NASDAQ |
Oct 20, 16:00
1.27
+0.01
(+0.79%)
After-Hours: 20:00
Celularity Research and Development Expense (TTM)
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 8.724M |
| December 31, 2025 | 9.222M |
| September 30, 2025 | 9.63M |
| June 30, 2025 | 8.876M |
| March 31, 2025 | 9.246M |
| December 31, 2024 | 11.22M |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 |
| Date | Value |
|---|---|
| September 30, 2023 | 34.45M |
| June 30, 2023 | 49.57M |
| March 31, 2023 | 66.32M |
| December 31, 2022 | 71.12M |
| September 30, 2022 | 84.65M |
| June 30, 2022 | 88.11M |
| March 31, 2022 | 86.06M |
| December 31, 2021 | 81.73M |
| September 30, 2021 | 71.74M |
| June 30, 2021 | 59.47M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Tenax Therapeutics, Inc. | 45.26M |
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 2.029M |
| Century Therapeutics, Inc. | 66.62M |
| Absci Corp. | 86.49M |